分子肿瘤学研究驱动癌症发生、发展和耐药性的遗传、表观遗传和生化改变。该领域整合了高通量测序、分子诊断和靶向治疗，以阐明致癌通路、抑癌基因失活和肿瘤微环境相互作用。分子谱分析、生物标志物发现和精准医学的进步重新定义了癌症的分类和治疗策略。以下汇编了最新的同行评审出版物和专利创新成果，反映了癌基因、信号转导、癌症干细胞、免疫调节和分子成像技术等领域的前沿研究，这些技术对于转化肿瘤学和临床应用至关重要。
这是我们最新精选的分子肿瘤学方面的全球英文出版物和专利，这些出版物和专利来自众多科学在线期刊，分类并侧重于癌基因、肿瘤抑制因子、信号转导通路、癌症基因组学、癌症表观遗传学、分子生物标志物、癌症靶向治疗、癌细胞信号转导、DNA 突变、肿瘤学中的 microRNA、癌症干细胞、细胞凋亡调控、肿瘤微环境、癌症免疫疗法、基因表达谱、染色体畸变、分子诊断、癌症蛋白质组学、致癌途径、癌症转移、致癌分子机制、肿瘤异质性、癌症表观基因组学、致癌病毒、分子靶向药物、癌症转录组学、DNA 修复机制、癌症药物基因组学和癌症分子病理学。.
Methods for predicting and improving the efficacy of car t-cell therapy
Patent published on the 2026-05-06 in EP under Ref EP4736874 by UNIV ZUERICH [CH] (Magnani Chiara Francesca [ch], Ponzo Marianna [ch], Gaipa Giuseppe [it], Biondi Andrea [it])
Abstract: [0001] Disclosed is a treatment with a combination of inhibitors useful to improve the effectiveness of CAR T-cell therapies by inhibiting hypoxia, VEGF pathways and inflammation at the tumor microenvironment, thereby enhancing the response to CAR T-cell therapy in tumor patients. There is also disclosed a method for predicting the response to CAR T-cell therapy by determining T cell surface expression markers.[...]
Our summary: The document discusses methods to enhance CAR T-cell therapy effectiveness through inhibitors targeting hypoxia, VEGF pathways, and inflammation. It also presents a predictive method for therapy response based on T cell surface expression markers. These approaches aim to improve patient outcomes in tumor treatments.
CAR T-cell therapy, efficacy prediction, tumor microenvironment, inhibitors
Patent
A fluid processing device for processing droplets
Patent published on the 2026-05-06 in EP under Ref EP4737004 by IMEC VZW [BE] (Yurt Abdulkadir [be], Set Ying Ting [be], Moloudi Reza [be], Vandevelde Bart [be])
Abstract: [0001] The present invention relates to a fluid processing device for processing droplets. The device comprises a plate-like structure comprising a plurality of functional pixels. Each functional pixel is adapted to perform multiple operations on a droplet located on the pixel. Specifically, each pixel can selectively carry out at least two of the following processing operations: manipulating the droplet (e.g., its position), applying heat to the droplet, and subjecting the droplet to a magnetic[...]
Our summary: The invention is a fluid processing device designed for droplet manipulation. It features a plate-like structure with functional pixels that can perform multiple operations on droplets. This device integrates various microfluidic functions into a compact platform for applications in biochemical analysis and drug discovery.
microfluidics, droplet manipulation, functional pixels, biochemical analysis
Patent
A simplified molecular diagnostic workflow for detecting human immunodeficiency virus 1 (hiv-1) and hepatitis c virus (hcv)
Patent published on the 2026-04-23 in WO under Ref WO2026081001 by HIS MAJESTY THE KING IN RIGHT OF CANADA AS REPRESENTED BY THE MINI OF HEALTH [CA] (Tang David [ca], Nguyen Kelvin [ca], Michalak Karen [ca], Lacap Phil [ca], Kim John [ca], Mclaren Paul [ca])
Abstract: Described herein is a singleplex RT-LAMP-based tests using modified primer sets. Contrived whole blood samples containing HIV-1 or HCV virions were diluted in equal parts water and loaded directly into optimized RT-LAMP master mixes. To mitigate cold-chain storage dependence, RT-LAMP reactions were performed using a lyophilized master mix. The reactions were heated for, for example 30 minutes using a hand-held, battery-powered heating device for simultaneous virion lysis and amplification.[...]
Our summary: This study presents a simplified workflow for detecting HIV-1 and HCV using singleplex RT-LAMP tests with modified primers. Whole blood samples containing the viruses were diluted and directly loaded into optimized master mixes. A lyophilized master mix allowed for reactions to be performed without cold-chain storage, using a portable heating device for amplification.
RT-LAMP, HIV-1, HCV, molecular diagnostics
Patent
Combination of cancer vaccines and anti-trem2 agents for enhanced cancer immunotherapy
Patent published on the 2026-04-23 in WO under Ref WO2026085270 by UNIV TEXAS [US] (Gubin Matthew [us])
Abstract: The present disclosure generally relates to methods for treating cancer, and more specifically to combinatorial approaches using cancer vaccines together with agents targeting the TREM2 receptor to enhance anti-tumor immune responses. The invention includes methods of administering cancer vaccines in combination with anti-TREM2 agents. This approach enhances anti-tumor immunity by expanding tumor-specific T cells while reducing immunosuppressive macrophages in the tumor microenvironment. Additio[...]
Our summary: This disclosure presents methods for treating cancer using a combination of cancer vaccines and anti-TREM2 agents. The approach enhances anti-tumor immunity by increasing tumor-specific T cells and decreasing immunosuppressive macrophages. It also explores the combination of these agents with immune checkpoint inhibitors for improved therapeutic outcomes.
cancer vaccines, anti-TREM2 agents, immunotherapy, tumor microenvironment
Patent
Docking peptides and related antibody-based drug conjugates
Patent published on the 2026-04-23 in US under Ref US20260109780 by SONNET BIOTHERAPEUTICS INC [US] (Cini John K [us], Evans Nick [gb])
Abstract: [0000] Provided herein are novel docking peptides and antibody-based drug conjugates that include such docking peptides. In embodiments, the subject docking peptide allows for the controlled attachment of one or more drug moieties and a tumor targeting moiety that allows for the targeting of the drug moiety to the tumor microenvironment. [0000] In some embodiments, the antibody-based drug conjugates provided herein advantageously allows for enhanced targeted delivery of a drug payload having a c[...]
Our summary: Novel docking peptides enable controlled attachment of drug moieties for targeted delivery. Antibody-based drug conjugates enhance drug payload delivery to tumor sites. The technology allows for a controlled drug-to-antibody ratio for improved therapeutic efficacy.
docking peptides, antibody-drug conjugates, tumor targeting, drug delivery
Patent
Nk cell-derived extracellular vesicles armed with modified monoclonal antibodies to target cancer cells, and use thereof
Patent published on the 2026-04-22 in EP under Ref EP4729126 by UNIV DE MONTPELLIER UM [FR] (Villalba Gonzalez MartÍn [fr], Campos Mora Mauricio [fr])
Abstract: [0001] The invention relates to NK cell-derived extracellular vesicles, as attractive candidates for new anti-tumor therapies. Natural killer (NK) cells participate in the anti-tumor immune response by recognizing and exerting cytolytic functions on target cells. Research has focused on taking advantage of these characteristics to generate NK cell-based immunotherapies to complement treatments with therapeutic monoclonal antibodies. However, in some environments, such as the tumor microenvironme[...]
Our summary: NK cell-derived extracellular vesicles are engineered with modified monoclonal antibodies to specifically target cancer cells. This approach enhances the anti-tumor immune response while mitigating the effects of the tumor microenvironment. The versatility of this strategy allows for potential applications beyond cancer, including infections and autoimmune diseases.
extracellular vesicles, NK cells, monoclonal antibodies, cancer therapy
Patent
Glioblastoma-Derived Extracellular Vesicles Modulate γδ T Lymphocytes Through a MIC-Dependent Mechanism
Published on 2026-02-03 by Micaela Rosato, Paula Saibene Vlez, Alejandra Infante Cruz, Matas A. Pibuel, Federico Fuentes, Mnica Vermeulen, Juan Iturrizaga, Pablo E. Espil, Silvia Berner, Gabriela V. Salamone, Carolina C. Jancic @MDPI
Abstract: Glioblastoma (GBM) is the most aggressive and common primary brain tumor, with a median survival of less than a year after diagnosis. γδ T lymphocytes are immune cells that can migrate to tumors and induce malignant cells’ apoptosis. Our previous in silico studies showed that higher γδ T-cell infiltration in GBM correlates with better patient survival, and in vitro experiments showed that GMB supernatants promote an antitumora[...]
Our summary: Glioblastoma-derived extracellular vesicles (EVs) modulate gamma delta T lymphocytes through a MIC-dependent mechanism. Increased CD69 expression, cytotoxicity, and cytokine production in T cells were observed following EV interaction. These findings offer insights for targeted immunotherapy development in glioblastoma patients.
Extracellular vesicles, Glioblastoma, Gamma delta T lymphocytes, Immunotherapy
Publication
Dynamic microRNA Signatures as Biomarkers for Cardiac Ischemia and Remodeling
Published on 2026-02-03 by Macarena Rodrguez-Serrano, Elena Martn-Garca, Patricia Alonso-Andrs, Elisa Conde-Moreno, Hctor Pian, Javier del Moral-Salmoral, Nunzio Alcharani, Miriam Menacho-Romn, Lorena Crespo-Toro, Miren Edurne Ramos-Muoz, Carlos Zaragoza, Luis Miguel Rincn, Mara G. Barderas, Mara Laura Garca-Bermejo @MDPI
Abstract: Myocardial infarction (MI) triggers complex pathological processes, including inflammation, hypoxia, and fibrotic remodeling. MicroRNAs (miRNAs) have emerged as promising biomarkers for cardiovascular injury; however, their expression dynamics along processes remain underexplored. We used an in vivo rat model of permanent coronary occlusion to study the molecular alterations associated with MI and its resolution in a temporal mode, including five experimental groups with five animals in each: sh[...]
Our summary: This study investigates the dynamic expression of microRNAs as biomarkers for cardiac ischemia following myocardial infarction. Using a rat model, it identifies specific miRNAs that correlate with the progression and resolution of myocardial injury over time. The findings suggest that these miRNA signatures can serve as noninvasive indicators of cardiac stress and potential therapeutic targets.
microRNA, cardiac ischemia, biomarkers, myocardial infarction
Publication
